Arxis, Inc. (ARXS) · Aug 18, 2026 · Acquisition
$770M acquisition — Approximately $770M enterprise value; 13.35M shares issued, or 3.1% dilution
Arxis completed its previously announced Omnetics purchase at a $770M enterprise value. The deal adds a specialized connector platform but dilutes shareholders.
The main event was already expected: closing, not a new deal. Arxis completed the previously announced Omnetics acquisition, so the filing confirms execution rather than changing the strategic outlook.
| Deal metric | Reported figure | Market read |
|---|---|---|
| Omnetics enterprise value | Approximately $770 million | Previously announced transaction value |
| Combined MagCanica and Omnetics purchase multiple | Approximately 12x FY27 estimated adjusted EBITDA | Forward valuation assumption, not a new operating result |
| Class A shares issued | 13,351,964 | Consideration paid partly in stock |
| New shares as a portion of common stock | Approximately 3.1% | Direct shareholder dilution |
The strategic asset fits Arxis’ existing playbook. Omnetics adds proprietary Micro-D-Sub and Nano-D-Sub connectors serving defense, space, aerospace, medical, and industrial customers, and will sit in the Electronic Components Segment. 〔0〕
The consideration was shareholder-friendly on financing, but not costless. Arxis used stock rather than describing new debt, and the filing says the recent share-price increase influenced the issuance; former Omnetics owners received 13.35 million shares locked up at closing. 〔1〕
What remains unproven is the return on the $770 million purchase price. The filing provides no Omnetics revenue, adjusted EBITDA, earnings contribution, synergy target, or updated leverage information, so investors cannot determine from this 8-K whether the transaction is accretive or whether the roughly 12x FY27 multiple is attractive versus current expectations. Net read: strategically coherent and successfully closed, but economically still a confirmation with meaningful dilution and no new operating evidence.
First reported quarter including Omnetics
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!